Thursday 21 / November / 2024
Washington [US]: American multinational technology company, Amazon has received Food and Drug Administration authorisation (FDA) for its COVID-19 test developed by its subsidiary STS Lab Holdco and the company is now intending to utilise it for its employee testing program.
According to The Verge, Amazon Company, which has got a green flag from FDA for its COVID-19 test kit is now planning to utilise it for its on-location Covid testing programs. The test is performed by utilising a nasal self swab that should be done either under the management of a medical services supplier or as a part of an at-home kit where a patient can take his/her own sample and then send it to an incorporated lab.
The FDA's authorisation, obtained by The Verge read, "Amazon plans to use the Amazon Real-Time RT-PCR Test for Detecting SARS-CoV-2 (Amazon Test) as part of the company's overall Coronavirus Disease 2019 (COVID-19) preparedness and response program."
The approval additionally portrays Amazon's worker screening program. Some Amazon workers will be naturally given testing appointments around every 14 days. The tests are voluntary.
"Amazon has partnered with a third-party healthcare provider who will issue the necessary prescriptions and individual test orders," the authorisation added.
The approval letter is routed to Cem Sibay, the VP of Amazon Labs. The previous summer, Amazon tapped Sibay to assemble its in-house COVID-19 testing lab, The Verge reported.
In October, the organisation said it had the foundation to run a huge number of tests for its employees every day.
The new test is an adjustment of another COVID-19 test made by BGI Genomics, which the authorisation said Amazon utilised at the end of August.
The Verge indicated that the organisation started utilising the modified version that would turn into the Amazon test on August 28th, 2020. Between late September and early December 2020, it ran more than 560,000 samples, as per the approval.
Amazon began selling at-home COVID-19 testing packs made by genomics organisation DxTerity in January. That test sells for USD 110. The organisation keeps on venturing into medical services: a week ago, it declared that it would begin offering its in-house telehealth and at-home medical services program to different organisations.
Amazon has likewise communicated interest in clinical testing previously. The Verge reported that back in 2018, the organisation was in converses with the purchase diagnostics organisation Confer Health.
